Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 801–900 of 1,000
Hannig, L. H., Nielsen, L. K., Ibsen, R., Arnheim‐Dahlström, L., Kjellberg, J., & Abildgaard, N. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13615 · Cited by 11
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 13
Jung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 15
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Terpos, E., Suzan, F., & Goldschmidt, H. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.021 · Cited by 11
Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
Fernández‐Lázaro, D., Fernandez-Lazaro, C. I., Caballero-García, A., & Córdova, A. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018001201444 · Cited by 15
Sher, T., Miller, K. C., Lee, K. P., & Chanan-Khan, A. A. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.065 · Cited by 11
Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)
Wiernik, P. H. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0077-x · Cited by 12
“• Two major studies of lenalidomide plus dexamethasone for treatment of relapsed and refractory multiple myeloma have recently been published [ 39 , 40].”
BackgroundResultSun, H., Atenafu, E. G., Yeboah, E., Reece, D. E., Trudel, S., Kukreti, V., Masih‐Khan, E., Winter, A., & Chen, C. I. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.915544 · Cited by 11
“Lenalidomide is an oral immunomodulatory agent approved for the treatment of relapsed or refractory MM in combination with dexamethasone, based on results from two large phase III trials [2,3].”
BackgroundTian, M., & Huang, H. (2017) · Medicine · doi:10.1097/md.0000000000009074 · Cited by 12
Anderson, S. M., Beck, B., Sterud, S., Lockhorst, R., & Ngorsuraches, S. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218758500 · Cited by 11
Egle, A., Steurer, M., Melchardt, T., Weiß, L., Gassner, F. J., Zaborsky, N., Geisberger, R., Catakovic, K., Hartmann, T. N., Pleyer, L., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3380-z · Cited by 11
“Since these observations were made at the 25-mg dose, previously established for multiple myeloma [10, 11], this led to a reassessment of lenalidomide dosing in CLL and the development program for the substance mandated a dosing schedule following slowly increasing doses in trials started from 2007 on.”
BackgroundChe, F., Chen, J., Dai, J., & Liu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s255682 · Cited by 12
Gaultney, J. G., Redekop, K., Sonneveld, P., & Groot, C. A. U. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.42 · Cited by 10
Reversible pulmonary toxicity due to lenalidomide
Coates, S., BARKER, A. R., & Spurgeon, S. E. F. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211408374 · Cited by 10
“Lenalidomide, a derivative of thalidomide, is FDAapproved for the treatment of Myelodysplastic Syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma (MM).(1,2,3) Lenalidomide hasmultiplemechanismsof action, including direct immune-modulatory effects, anti-angiogenesis activity…”
BackgroundDevelopment of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future
Landgren, O., & Rajkumar, S. V. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.009 · Cited by 10
Liu, L., Zhao, N., Xu, W., Sheng, Z., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0286-x · Cited by 11
“In the 422 response evaluable patients, the ORRs of 80 % derived from ERD (ELO/ LEN/DEX) was encouraging, which compared favorably with that of 60 to 61 % reported in the two trials of RD (LEN/DEX) [26, 27].”
ResultMultiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting
Santoleri, F., Lasala, R., Ranucci, E., Rocchi, M., Pulini, S., Morelli, A. M., Spadano, A., & Costantini, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220980807 · Cited by 10
“6months, respectively.(7) One year after the start of treatment, patients in OS were 77% and 75% respectively in MM-009 and MM010.”
BackgroundLazaryan, A., Hussein, M. A., Reu, F. J., Faiman, B. M., Habecker, B., Karam, M. A., Reed, J., Hamilton, K. M., Waksman, J. A., Bruening, K., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23639 · Cited by 10
“Although the DVd-R regimen was generally well tolerated, a VTE risk of 4% despite mandatory aspirin use argues for maintaining VTE prophylaxis in patients with RRMM during lenalidomide maintenance therapy.”
BackgroundSelf-citationNeuropathies in the context of malignancies
Béhin, A., Psimaras, D., Hoang‐Xuan, K., & Léger, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32830f226d · Cited by 10
Mele, G., Melpignano, A., Quarta, G., Palumbo, G. A., Capalbo, S. F., Falcone, A. P., Cascavilla, N., Palazzo, G., Mazza, P., Iannitto, E., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.007 · Cited by 10
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. P. (2012) · Future Oncology · doi:10.2217/fon.12.124 · Cited by 10
KMF investigators, Kobayashi, T., Kuroda, J., Fuchida, S., Kaneko, H., Yagi, H., Shibayama, H., Tanaka, H., Kosugi, S., Uoshima, N., et al. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1696-6 · Cited by 12
“Two phase III trials (MM-009 and MM-010) demonstrated that lenalidomide plus dexamethasone was more effective than dexamethasone alone in patients with RRMM [8, 9].”
BackgroundResultIndicaciones terapéuticas actuales de la talidomida y la lenalidomida
Ordi‐Ros, J., & Cosiglio, F. J. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.04.038 · Cited by 10
Spina, F., Montefusco, V., Crippa, C., Citro, A., Sammassimo, S., Olivero, B., Gentili, S., Galli, M., Guglielmelli, T., Rossi, D., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.564695 · Cited by 10
“However, both MM009 and MM010 studies included a substantial proportion of patients who received lenalidomide after only one line of therapy, and it is still unknown whether longterm responses to lenalidomide are possible in patients treated after a second or third line [4,5,7].”
BackgroundResultLeleu, X. P., Terpos, E., García‐Sánz, R., Cooney, J. P., O’Gorman, P., Minařík, J., Greil, R., Williams, C. D., Gray, D., & Szabó, Z. R. (2016) · American Journal of Hematology · doi:10.1002/ajh.24416 · Cited by 11
“Assuming an incidence of grade 3/4 neutropenia of 40% based on the literature [8,9,19], a sample size of 200 patients (allowing a 6% dropout rate) would enable 95% confidence intervals to be calculated to within a precision of 67%.”
BackgroundResultTreatment of Relapsed/Refractory Multiple Myeloma
Neri, P. E., Bahlis, N. J., Paba‐Prada, C. E., & Richardson, P. G. G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_10 · Cited by 10
Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects
Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 11
“In non-hyperdiploid states, translocations are the predominant chromosomal changes, such as t(11;14), t(4;14), and t(14;16), respectively, and account for approximate 40– 50% of primary events.”
BackgroundMark, T. M., Guarneri, D., Forsberg, P. A., Rossi, A., Pearse, R. N., Perry, A., Pekle, K. A., Tegnestam, L., Greenberg, J., Shore, T. B., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.007 · Cited by 10
Hurtado-de-Mendoza, D., Loaiza‐Bonilla, A., Bonilla-Reyes, P. A., & Alcorta, R. (2017) · Cureus · doi:10.7759/cureus.1258 · Cited by 10
“Administered as a single agent, it is not associated with an increased risk of thrombotic events [6, 158].”
BackgroundThe predictive value of serum myeloma protein in solitary plasmacytoma
Chang, W. I., Koh, H. K., Yoon, S., Kim, H., Eom, K., & Kim, I. H. (2020) · Radiation Oncology Journal · doi:10.3857/roj.2019.00570 · Cited by 11
“5 g/dL from nadir to define disease progression [16,17].”
BackgroundDimopoulos, M. A., Mikhael, J. R., Terpos, E., Leleu, X. P., Moreau, P., Bladé, J., Kim, J. S., Stockerl-Goldstein, K. E., & Richardson, P. G. G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221088458 · Cited by 10
Self-citationMankikian, J., Lioger, B., Diot, É., d'Halluin, P., Lissandre, S., Marchand-Adam, S., Mercier, E., & Beau-Salinas, F. (2013) · Heart & Lung · doi:10.1016/j.hrtlng.2013.11.007 · Cited by 10
Offidani, M., Corvatta, L., Morabito, F., Gentile, M., Musto, P., Leoni, P., & Palumbo, A. P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.575060 · Cited by 10
“Is it the same also for rrMM? The CR rate with approved single or two agent therapies for rrMM such as bortezomib [23,] lenalidomide [24], bortezomibdoxil [25] and lenalidomide-dexamethasone [26,27] ranges from 2 to 15% and TTP from 5 to 11 months.”
BackgroundDiffuse alveolar hemorrhage associated with lenalidomide
Sakai, M., Kubota, T., Kuwayama, Y., Ikezoe, T., & Yokoyama, A. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0871-2 · Cited by 10
“Lenalidomide is a potent anti-cancer agent that is widely used in patients with refractory or relapsed multiple myeloma [1].”
BackgroundRivell, G. L., Brunson, C. Y., Milligan, L., Stuart, R. K., & Costa, L. J. (2011) · American Journal of Hematology · doi:10.1002/ajh.22054 · Cited by 11
5q− syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide
Ortega, M., Mallo, M., Solé, F. G., Sánchez-Morata, C., López-Andreoni, L., Martínez-Morgado, N., Gironella, M., Valcárcel, D., & Vallespı́, T. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.06.021 · Cited by 10
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Ray, E. L., Jagannath, S., & Palumbo, A. P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1119041 · Cited by 10
Maintenance therapy in multiple myeloma
Mewawalla, P., & Chilkulwar, A. R. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716677244 · Cited by 10
Safety issues and management of toxicities associated with new treatments for multiple myeloma
Brioli, A., Mügge, L., Hochhaus, A., & von Lilienfeld‐Toal, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284584 · Cited by 11
“This rate was similar to the one reported with lenalidomide and dexamethasone but higher than that reported with bortezomib and dexamethasone [36,37].”
ResultKobayashi, T., Miura, M., Niioka, T., Abumiya, M., Ito, F., Kobayashi, I., Ikeda, S., Yoshioka, T., Kameoka, Y., & Takahashi, N. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000499 · Cited by 10
Iskierka‐Jazdzewska, E., Canzian, F., Stępień, A., Martino, A., Campa, D., Stein, A., Krawczyk‐Kuliś, M., Rybicka‐Ramos, M., Kyrcz‐Krzemień, S., Butrym, A. K., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1689391 · Cited by 10
Wang, B., Duan, J., & Zhou, L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001041 · Cited by 10
Bringhen, S., Gay, F., Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712685 · Cited by 11
Weisel, K. C., & Kanz, L. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_21 · Cited by 11
Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282624 · Cited by 9
“Lenalidomide (an immunomodulatory agent) and bortezomib (a proteasome inhibitor) are backbones of pharmacotherapy for NDMM. 1,5 11-13 The efficacy and tolerability of lenalidomide + dexamethasone (Rd) in NDMM have been demonstrated in multiple trials, including the phase III FIRST study, which…”
MethodSelf-citationRelapsed and Refractory Multiple Myeloma
Gentili, S., & Lonial, S. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.008 · Cited by 10
Shen, X., Zhang, L., Wang, J., Chen, L., Liu, S. Y., & Zhang, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1052903 · Cited by 9
Small bowel bleeding: clinical diagnosis and management in the elderly
Oka, P., Ray, M., & Sidhu, R. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2214726 · Cited by 11
“It is widely used in the management of multiple myeloma and myelodysplastic syndrome [73].”
BackgroundHatakeyama, K., Kikushige, Y., Ishihara, D., Yamamoto, S., Kawano, G., Tochigi, T., Miyamoto, T., Sakoda, T., Christoforou, A., Kunisaki, Y., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010080 · Cited by 11
“1,11,12,30 Therefore, we examined whether there is any effect of dexamethasone on THBS-1.”
BackgroundTreatment options for mantle cell lymphoma
Smolewski, P., Witkowska, M., & Robak, T. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1087507 · Cited by 9
An update on the use of lenalidomide for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067681 · Cited by 9
Self-citationChallenges in multiple myeloma diagnosis and treatment
Girnius, S. K., & Munshi, N. C. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.2 · Cited by 10
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Vij, R. (2011) · PubMed · Cited by 9
Joao, C. M., de Freitas, J. G., Gomes, F. M. R., Geraldes, C., Coelho, I., Neves, M. L., Lúcio, P., Esteves, S., & Esteves, G. V. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2662-6 · Cited by 9
Thromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review
Al‐Ani, F., Louzada, M., Bastida, J. M., & Mateos, M. (2015) · Blood · doi:10.1182/blood.v126.23.2321.2321 · Cited by 9
“It is becoming the new backbone for myeloma treatment both in clinical trials and in clinical practice [7–11].”
BackgroundInfluentialIida, S., Wakabayashi, M., Tsukasaki, K., Miyamoto, K., Maruyama, D., Yamamoto, K., Takatsuka, Y., Kusumoto, S., Kuroda, J., Ando, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13550 · Cited by 9
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Diamond, B. T., Maclachlan, K. H., Chung, D. J., Lesokhin, A. M., & Landgren, O. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101140 · Cited by 9
Cao, Y., Zhao, L., Zhang, T., & Cao, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.608685 · Cited by 9
“2) was used to extract the graphical data from the PFS and OS Kaplan–Meier curves of D-VMP and VMP, then we reconstructed individual patient data (IPD) and used the extracted values and number at risk to simulate through Weibull, log-normal, log-logistic, logistic to select the best simulation curve based on the Akaik…”
MethodDong, L., Yao, J., Wang, X., Shan, K., Yang, H. S., Yan, B., & Jiang, Q. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.014 · Cited by 9
Chemotherapy-Associated Thrombosis
Ashrani, A. A., & Rajkumar, S. V. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-79962-9_11 · Cited by 9
“However, when administered concurrently with dexamethasone, the incidence of VTE was higher, ranging from 9% to 15% in phase III studies [73, 74].”
BackgroundBaz, R., Shain, K. H., Hussein, M. A., Lee, J., Sullivan, D. M., Oliver, E. F., Nardelli, L. A., Nodzon, L., Zhao, X., Ochoa-Bayona, J. L., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23587 · Cited by 10
Multiple myeloma: detecting the effects of new treatments
Djulbegović, B., & Kumar, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60704-7 · Cited by 9
Martin, M. G., & Vij, R. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.063 · Cited by 9
Zelis, N., Devos, T., Dierickx, D., Janssens, A., Raddoux, J., Verhoef, G. E. G., & Delforge, M. (2014) · Acta Clinica Belgica · doi:10.1179/0001551214z.00000000030 · Cited by 9
Azaïs, I., Brault, R., & Debiais, F. (2009) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.10.009 · Cited by 9
Drug-induced Interstitial Pneumonitis due to Low-dose Lenalidomide
Kunimasa, K., Ueda, T., Arita, M., Maeda, T., Hotta, M., & Ishida, T. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6651 · Cited by 9
“/2011(9) not performed interstitial pneumonia median: 6 (1-24) dyspnea, cough, fever NA D/C lenalidomide improved * 8 case reports corticosteroid D/C=discontinued NA=not available Figure 3.”
BackgroundBerenson, J. R., & Yellin, O. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283090475 · Cited by 9
Should minimal residual disease negativity be the end point of myeloma therapy?
Anderson, K. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000117 · Cited by 12
The importance of antiangiogenic effect in multiple myeloma treatment
Barchnicka, A., Olejniczak‐Nowakowska, M., Krupa-Kotara, K. H., & Grosicki, S. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/68826 · Cited by 9
Périchou, J., Ranchon, F., Herledan, C., Huot, L., Larbre, V., Carpentier, I., Lazareth, A., Karlin, L., Beny, K., Vantard, N., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243309 · Cited by 9
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Cancer Reviews · doi:10.3816/ccr.2009.n.008 · Cited by 9
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
“1–4, 9–12, and 17–20 for the first four cycles then on days 1–4 only for subsequent cycles) [99,100].”
BackgroundPaumgartten, F. J. R. (2019) · Ciência & Saúde Coletiva · doi:10.1590/1413-812320182410.28522017 · Cited by 9
Gay, F., Rajkumar, S. V., Falco, P., Kumar, S. K., Dispenzieri, A. A., Petrucci, M. T., Gertz, M. A., Boccadoro, M., Stewart, A. K., & Palumbo, A. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01469.x · Cited by 8
“Lenalidomide has fewer non-hematologic side effects compared to the parent drug and a more predictable and manageable toxicity profile (5, 6).”
BackgroundIida, S., Izumi, T., Komeno, T., Terui, Y., Chou, T., Ikeda, T., Berg, D. T., Fukunaga, S., Sugiura, K., & Sasaki, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02030-7 · Cited by 8
Advancements in the Treatment of Multiple Myeloma
Zavaleta‐Monestel, E., Quesada-Villaseñor, R., Barrantes-López, M., Arguedas‐Chacón, S., Campos-Hernández, J., Rojas-Chinchilla, C., García-Montero, J., Castro-Ulloa, J., Anchía-Alfaro, A., & Montenegro-Chaves, J. R. (2024) · Cureus · doi:10.7759/cureus.74970 · Cited by 12
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, A. M., Vicuña, I., & Aguado, B. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7275 · Cited by 10
Ludwig, H., & Sonneveld, P. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70006-1 · Cited by 9
Harousseau, J., & Mohty, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6 · Cited by 8
Self-citationMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 9
Stino, A. M., Bumma, N., Smith, R. M., Davalos, L., Allen, J. A., Ye, J. C., Pianko, M. J., Campagnaro, E. L., Fierro, C., Awad, A., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.16164 · Cited by 8
“In general, previous lenalidomide studies in multiple myeloma show DVT and PE frequencies ranging from 4%–11.9% to 3.4%–4.4%, respectively [28, 29], which are reduced to 1% with a risk-adapted approach to prophylaxis [ 30 ], and an overall VTE incidence of 7% in primary or light chain amyloidosis…”
BackgroundInfluentialPhase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
Ocio, E. M., Oriol, A., Bladé, J., Teruel, A. I., Martín, J., de la Rubia, J., Gutierrez, N. C., Díaz‐Pavón, J. R., González, S. M., Coronado, C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13515 · Cited by 8
“…of multiple myeloma (MM) associated with the recent introduction of immunomodulatory drugs (IMIDs), such as thalidomide or lenalidomide, and proteasome inhibitors (PIs), such as bortezomib (Richardson et al, 2003; Dimopoulos et al, 2007), MM remains incurable and virtually all patients relapse.”
BackgroundSelf-citationManagement of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide
Miller, K. C., Musial, L., Whitworth, A., & Chanan-Khan, A. A. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.491-499 · Cited by 8
A practical approach to relapsed multiple myeloma
Mikhael, J. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.262 · Cited by 8
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Blumel, S., & Broadway-Duren, J. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.4.4 · Cited by 8
“…received one or more prior therapies and as a single agent for transfusion-dependent anemia due to low-/intermediate-1–risk myelo-dysplastic syndrome (MDS) associated with deletion 5q with/without additional cytogenetic abnormalities (Dimopoulos et al., 2007; Celgene, 2013; Weber et al., 2007).”
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Bruno, B., Giaccone, L., Sorasio, R., & Boccadoro, M. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.001 · Cited by 12
“(2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.”
BackgroundKawamura, K., Ikeda, T., Hagiwara, S., Mori, T., Shinagawa, A., Nishiwaki, K., Ohashi, K., Kubonishi, S., Fukuda, T., Ito, T., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1154958 · Cited by 8
Garderet, L., Cook, G., Auner, H. W., Bruno, B., Lokhorst, H. M., Pérez‐Simón, J. A., Sahebi, F., Scheid, C., Morris, C., van Biezen, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228926 · Cited by 8
“[7] The secondgeneration IMiD, lenalidomide, was reported in two pivotal studies published in 2007 with similar results.[8,9] Lenalidomide plus dexamethasone induces a partial response or better of 60% with a time to progression of 11 months.”
Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia
Bertrand, E., Jouy, N., Manier, S., Fouquet, G., Guidez, S., Boyle, E. M., Noel, S., Tomowiak, C., Herbaux, C., Schraen‐Maschke, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22872 · Cited by 8
Lee, S., Lim, J., Ryu, D., Kim, T., Park, S. S., Jeon, Y., Yoon, J., Cho, B., Eom, K., Kim, Y., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3401-y · Cited by 8
“In particular, the combination of lenalidomide and high-dose dexamethasone (Len-Dex) demonstrated efficacy and safety in patients with relapsed/refractory MM in two large, welldesigned pivotal clinical trials [10, 11] .”
BackgroundKimura, S., Ohkawara, H., Ogawa, K., Tanaka, M., Sano, T., Harada‐Shirado, K., Takahashi, H., Ueda, K., Shichishima-Nakamura, A., Matsumoto, H., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1018-18 · Cited by 9
“Lenalidomide, an immunomodulatory drug, has been shown to improve the outcomes of patients with newlydiagnosed, previously-treated or refractory MM (8-10).”
BackgroundMechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Nooka, A. K., & Lonial, S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000354 · Cited by 8
Patel, J. N., Robinson, M. M., Jagosky, M. H., Slaughter, D., Arnall, J. R., Jandrisevits, E., Matusz‐Fisher, A., Atrash, S., Paul, B. A., Bhutani, M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.015 · Cited by 8
Thromboprophylaxis in multiple myeloma: is the evidence there?
Kristinsson, S. Y., & Landgren, O. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.214 · Cited by 8
Managing multiple myeloma in the elderly: are we making progress?
Quach, H., Prince, H. M., & Spencer, A. G. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.18 · Cited by 10
Self-citationLenalidomide-induced cytokine release syndrome in a patient with multiple myeloma
Nakamura, N., Kanemura, N., Shibata, Y., Matsumoto, T., Mabuchi, R., Nakamura, H., Kitagawa, J., Goto, N., Hara, T., Tsurumi, H., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.853300 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Grandoni, F., Stalder, G., Kaeser, A. B., Ribi, C., Cairoli, A., & Blum, S. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1620945 · Cited by 8
“Rash appeared to be less common with pomalidomide than with lenalidomide [6,7].”
BackgroundMerz, A. M. A., Merz, M., Hillengaß, J., Holstein, S. A., & McCarthy, P. L. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1674142 · Cited by 8
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.